Immunic Grants Major Stock Package to CFO in Retention Move

Rhea-AI Filing Summary

Immunic CFO Glenn Whaley filed an amended Form 4 (Form 4/A) to correct a previously reported stock option grant from June 5, 2025. The amendment addresses an administrative error in the number of options reported in the original filing dated June 9, 2025.

Key details of the corrected transaction:

• Granted 503,500 stock options at an exercise price of $0.7729 per share
• Options expire on June 5, 2035
• Vesting schedule: 25% vests after one year, with remaining vesting monthly over 36 months

The direct ownership of these derivative securities provides long-term equity incentive alignment between the CFO and shareholders. The relatively low exercise price suggests the company's stock may be trading at modest levels, though this grant represents a significant equity position for a C-level executive.

Positive

• CFO Glenn Whaley received a significant stock option grant of 503,500 shares at $0.7729 per share, representing a strong alignment with shareholder interests through performance-based vesting over 4 years

Negative

• None.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Whaley Glenn

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	503,500	$0.00	--

Holdings After Transaction: Stock Option — 503,500 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whaley Glenn

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/09/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.7729	06/05/2025		A		503,500		(1)	06/05/2035	Common Stock	503,500	$0.00	503,500	D

Explanation of Responses:

1. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

Remarks:

This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.

	/s/ Glenn Whaley	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to IMUX's CFO Glenn Whaley in June 2025?

According to the Form 4/A filing, IMUX's CFO Glenn Whaley was granted 503,500 stock options on June 5, 2025, with an exercise price of $0.7729 per share. These options expire on June 5, 2035.

What is the vesting schedule for Glenn Whaley's IMUX stock options granted in June 2025?

The stock options vest over 4 years with the following schedule: 25% of the shares vest on the first anniversary of the grant date (June 5, 2026), and the remaining 75% vest in equal monthly increments over the following 36 months.

Why did IMUX file an amended Form 4 (Form 4/A) for CFO Glenn Whaley?

IMUX filed a Form 4/A on June 28, 2025, to correct an administrative error in the original Form 4 filed on June 9, 2025. The amendment was specifically made to correct the incorrectly reported number of stock options granted to CFO Glenn Whaley.

What is the exercise price of IMUX CFO's June 2025 stock option grant?

The stock options granted to IMUX's CFO Glenn Whaley have an exercise price of $0.7729 per share.